# BlissBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blissbio

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.blissbiopharma.com
- Total disclosed funding: $77M
- Latest round: Series B (Jan 18, 2023)
- Investors on record: 5

## About

Established in 2017 and based in Hangzhou, China, BlissBio operates as an oncology targeted and immunotherapy drugs developer that provides oncology targeted and immunotherapy drugs. In 2019, the first antibody-drug conjugate (ADC) project enters FDA clinical trial and IND filing stage. The company cooperates with Eisai Morphotek Japan. In December 2022, the company was recognized as a national high-tech enterprise. In June 2023, it raised an undisclosed amount of series B++ funding fromEisai. Ziping Wei, the co-founder and CEO of the company, and she once served as the past president of the Chinese biopharmaceutical technology association of America (CBA). Yuhong Zhou, the co-founder and CSO of BlissBio, and she has B.S. in biochemistry and M.S. in genetics from Fudan University.

The company provides oncology targeted and immunotherapy drugs. Its product includes product pipeline for antibody-coupled drug ADCs, including BB-1701, BB-1705 and BB-1709. BB-1701 is a HER2 antibody-drug conjugate and it has a marketed drug toxin Eribulin. It technology platforms are divided into four series, which include pre- clinical research platform, process development platform, quality research platform and GMP production platform. Pre- clinical research platform includes design and screening of lead antibodies, small molecule payloads and linkers, and genetic engineering and modification of fixed-point coupled antibodies. Quality research platform adopts high-resolution LC-MS, molecular interaction analyzer, automatic capillary electrophoresis analysis system, UPLC and multi-functional enzyme marker equipment. GMP production platform has passed the quality standard system required by US FDA, EU EMA and China NMPA.

## Funding rounds

- Series B, Jan 18, 2023, $15M — Oriental Fortune Capital, In Capital, Sherpa Healthcare Partners
- Series B, Apr 16, 2021, $62M — Oriental Fortune Capital, Changce Investment
- Series A, Nov 14, 2019 — Alwin Capital, Sherpa Healthcare Partners

## Investors

- Alwin Capital — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series B
- Changce Investment — Series B
- In Capital — Series B